| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1038985905 |
| P356 | DOI | 10.1007/S00345-014-1317-2 |
| P698 | PubMed publication ID | 24825472 |
| P50 | author | Marianne Schmid | Q87169715 |
| Felix Chun | Q39979798 | ||
| P2093 | author name string | Jens Hansen | |
| Markus Graefen | |||
| Quoc-Dien Trinh | |||
| Margit Fisch | |||
| P2860 | cites work | Additional value of PCA3 density to predict initial prostate biopsy outcome | Q87239892 |
| The roles of multiparametric magnetic resonance imaging, PCA3 and prostate health index-which is the best predictor of prostate cancer after a negative biopsy? | Q87274656 | ||
| Systematic review of complications of prostate biopsy | Q26822966 | ||
| Cancer statistics, 2014 | Q27861018 | ||
| Screening and prostate-cancer mortality in a randomized European study | Q29617485 | ||
| Declining death rates reflect progress against cancer | Q33541029 | ||
| A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam | Q33558289 | ||
| Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer | Q33672510 | ||
| Risk factors for prostate cancer detection after a negative biopsy: a novel multivariable longitudinal approach | Q33770342 | ||
| A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness | Q33839248 | ||
| Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication | Q33897630 | ||
| Free prostate-specific antigen in serum is becoming more complex | Q34130219 | ||
| Family history and the risk of prostate cancer | Q34268953 | ||
| Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter | Q34323096 | ||
| Prostate cancer incidence and mortality rates and trends in the United States and Canada | Q34756568 | ||
| Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy | Q34792453 | ||
| Predicting prostate cancer risk through incorporation of prostate cancer gene 3. | Q34809531 | ||
| A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range | Q35119292 | ||
| Obesity is a significant risk factor for prostate cancer at the time of biopsy | Q35231117 | ||
| Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer | Q35535776 | ||
| Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. | Q35632848 | ||
| Recent trends in prostate cancer incidence by age, cancer stage, and grade, the United States, 2001-2007 | Q36449643 | ||
| Tumor markers in prostate cancer I: blood-based markers | Q36607766 | ||
| Role of nomograms for prostate cancer in 2007. | Q36749371 | ||
| Challenges of cancer biomarker profiling | Q36962561 | ||
| Obesity and future prostate cancer risk among men after an initial benign biopsy of the prostate | Q36968554 | ||
| New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer | Q36973830 | ||
| Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. | Q36998577 | ||
| New circulating biomarkers for prostate cancer | Q36999680 | ||
| Updating risk prediction tools: a case study in prostate cancer | Q37025404 | ||
| Sarcosine as a potential prostate cancer biomarker--a review | Q37091881 | ||
| Role of prostate volume in the early detection of prostate cancer in a cohort with slowly increasing prostate specific antigen | Q37094671 | ||
| Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. | Q37109209 | ||
| Inventory of prostate cancer predictive tools | Q37125852 | ||
| Exclusion of inflammation in the differential diagnosis of an elevated prostate-specific antigen (PSA). | Q37359271 | ||
| TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia | Q37460447 | ||
| Cancer-associated changes in the expression of TMPRSS2-ERG, PCA3, and SPINK1 in histologically benign tissue from cancerous vs noncancerous prostatectomy specimens | Q37527876 | ||
| Potential Urinary Protein Biomarker Candidates for the Accurate Detection of Prostate Cancer among Benign Prostatic Hyperplasia Patients | Q37540974 | ||
| Smoking and prostate cancer in a multi-ethnic cohort | Q37597408 | ||
| Tumour markers in prostate cancer III: biomarkers in urine. | Q37878473 | ||
| Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. | Q37922910 | ||
| Prostate cancer: multiparametric MR imaging for detection, localization, and staging. | Q37935483 | ||
| Optimising repeat prostate biopsy decisions and procedures | Q37970859 | ||
| Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion | Q37975853 | ||
| Genetic analysis of the principal genes related to prostate cancer: a review | Q38058970 | ||
| EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. | Q38160994 | ||
| Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detection | Q38385612 | ||
| Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater | Q39535872 | ||
| Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial | Q39752227 | ||
| Development and external validation of an extended 10-core biopsy nomogram | Q39770203 | ||
| Development and external validation of an extended repeat biopsy nomogram | Q39782032 | ||
| Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer | Q39811511 | ||
| The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam | Q39843624 | ||
| Evaluation of the ETS-related gene mRNA in urine for the detection of prostate cancer | Q39919769 | ||
| Development and validation of a nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session in the era of extended prostate sampling | Q39931294 | ||
| Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting | Q39978620 | ||
| Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions | Q39979486 | ||
| Development of improved nomogram for prediction of outcome of initial prostate biopsy using readily available clinical information | Q39988569 | ||
| Cost-effectiveness of Prostate Health Index for prostate cancer detection | Q40007049 | ||
| Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay | Q40053548 | ||
| Development and internal validation of a Prostate Health Index based nomogram for predicting prostate cancer at extended biopsy. | Q40057434 | ||
| Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer | Q40077903 | ||
| Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer. | Q40078607 | ||
| Prediction of the risk of harboring prostate cancer by a prebiopsy nomogram based on extended biopsy protocol | Q40084388 | ||
| Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy. | Q40096187 | ||
| The measurement of psychological distress in men being investigated for the presence of prostate cancer | Q40100450 | ||
| Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial | Q40116383 | ||
| The presence of prostate cancer at biopsy is predicted by a number of genetic variants | Q40137412 | ||
| Nomogram using transrectal ultrasound-derived information predicting the detection of high grade prostate cancer on initial biopsy | Q40149911 | ||
| Relationship of chronic histologic prostatic inflammation in biopsy specimens with serum isoform [-2]proPSA (p2PSA), %p2PSA, and prostate health index in men with a total prostate-specific antigen of 4-10 ng/ml and normal digital rectal examination | Q40156084 | ||
| Fluctuation in prostate cancer gene 3 (PCA3) score in men undergoing first or repeat prostate biopsies | Q40167317 | ||
| Risk factors for prostate cancer. | Q40286671 | ||
| The impact of repeat biopsies on infectious complications in men with prostate cancer on active surveillance | Q42248387 | ||
| A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. | Q43739468 | ||
| Multicenter European external validation of a prostate health index-based nomogram for predicting prostate cancer at extended biopsy | Q45033695 | ||
| PCA3 score of 20 could improve prostate cancer detection: results obtained on 734 Italian individuals. | Q45369120 | ||
| Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. | Q45952128 | ||
| Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer | Q46605938 | ||
| Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy | Q46632925 | ||
| Cancer survival among US whites and minorities: a SEER (Surveillance, Epidemiology, and End Results) Program population-based study | Q46706529 | ||
| A graphical device to represent the outcomes of a logistic regression analysis. | Q47392558 | ||
| Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends | Q47787102 | ||
| Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower | Q48513543 | ||
| Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROME | Q50858265 | ||
| Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. | Q51780643 | ||
| TMPRSS2-ERG Fusion Prostate Cancer: An Early Molecular Event Associated With Invasion | Q57693484 | ||
| The Biology and Natural History of Prostate Cancer: A Short Introduction | Q58813347 | ||
| Overdiagnosis Due to Prostate-Specific Antigen Screening: Lessons From U.S. Prostate Cancer Incidence Trends | Q61881628 | ||
| Recent trends in prostate cancer testing and incidence among men under age of 50 | Q64126984 | ||
| Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer | Q71606146 | ||
| Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? | Q74591846 | ||
| Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing | Q78508122 | ||
| Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach | Q80818866 | ||
| Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy | Q82585676 | ||
| Discrepancy in prostate cancer localization between biopsy and prostatectomy specimens in patients with unilateral positive biopsy: implications for focal therapy | Q82914436 | ||
| A meta-analysis of the performance characteristics of the free prostate-specific antigen test | Q83115184 | ||
| Diagnosis of isolated high-grade prostatic intra-epithelial neoplasia: proposal of a nomogram for the prediction of cancer detection at saturation re-biopsy | Q84899240 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostate cancer | Q181257 |
| biomarker | Q864574 | ||
| P304 | page(s) | 871-880 | |
| P577 | publication date | 2014-05-14 | |
| P1433 | published in | World Journal of Urology | Q15750774 |
| P1476 | title | The role of biomarkers in the assessment of prostate cancer risk prior to prostate biopsy: which markers matter and how should they be used? | |
| P478 | volume | 32 |
| Q40237929 | Comparative Study of Blood-Based Biomarkers, α2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection |
| Q37267205 | Prostate tumor attenuation in the nu/nu murine model due to anti-sarcosine antibodies in folate-targeted liposomes |
| Q26777066 | Sniffing out prostate cancer: a new clinical opportunity |
Search more.